Tempus AI, Inc. (TEM)
Market Cap | 9.36B |
Revenue (ttm) | 693.40M |
Net Income (ttm) | -746.33M |
Shares Out | 173.03M |
EPS (ttm) | -6.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 9,202,402 |
Open | 55.50 |
Previous Close | 57.06 |
Day's Range | 52.88 - 55.55 |
52-Week Range | 22.89 - 91.45 |
Beta | n/a |
Analysts | Buy |
Price Target | 61.10 (+13.0%) |
Earnings Date | May 6, 2025 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]
Financial Performance
In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $61.1, which is an increase of 13.00% from the latest price.
News

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-po...

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its su...

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Anal...

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-foc...

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including on...

Tempus to Report First Quarter 2025 Financial Results on May 6
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on...

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collabora...

Tempus AI: Cooldown Arrived (Rating Upgrade)
Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including ...

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Adviso...

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...

Is it safe to buy the Tempus AI stock dip now?
Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunge...

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exh...

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual...

Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth...

Tempus Announces Acquisition of Deep 6 AI
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a le...

Tempus AI: Buying The Dip After 2025 Guidance Raise
Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcar...

Tempus AI Earnings: A Promising Business, But There Are Risks
Tempus AI's core business growth is slowing, raising doubts about its AI-led narrative and long-term sustainable growth rates. Despite impressive revenue growth projections, Tempus AI remains free cas...

Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer ...

Tempus Reports Fourth Quarter and Full Year 2024 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge
Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.

3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ...

Tempus to Present at TD Cowen's 45th Annual Health Care Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health...

Ares Management Upsizes Tempus Debt Facilities to $560 Million
NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent...

Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves l...

Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technolo...